OS Therapies reports statistically significant 3-year OS benefit in Phase 2b
OS Therapies said Phase 2b results in herlystic(TM)-treated pulmonary metastatic osteosarcoma patients showed a statistically significant final three-year overall survival benefit.
Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated PatientsGrasonville, Maryland--(. - October 6, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunoth…